B. Cherubini

HBsAg kinetics in chronic hepatitis D during interferon therapy: on‐treatment prediction of response

Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance

A Randomized, Open-Label Clinical Study of Combined Pegylated Interferon Alfa-2a (40KD) and Entecavir Treatment for Hepatitis B "e" Antigen-Positive Chronic Hepatitis B

Hepatocellular carcinoma

Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dog

Ultrasound elastography: liver

Burden of liver diseases in the world

New insight in the pathobiology of hepatitis B virus infection

Elastography Assessment of Liver Fibrosis: Society of Radiologists in Ultrasound Consensus Conference Statement

The role of quantitative hepatitis B surface antigen revisited

Prediction Models of Long-Term Cirrhosis and Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients: Risk Scores Integrating Host and Virus Profiles

A predictive value of quantitative HBsAg for serum HBV DNA level among HBeAg-positive pregnant women

Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome

Virus associated malignancies: The role of viral hepatitis in hepatocellular carcinoma

Hepatitis B surface antigen quantification: Why and how to use it in 2011 – A core group report

Shear-Wave Elastography for the Estimation of Liver Fibrosis in Chronic Liver Disease: Determining Accuracy and Ideal Site for Measurement

Quantification of HBsAg in nucleos(t)ide-naïve patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study

Targeting the Achilles heel of the hepatitis B virus: a review of current treatments against covalently closed circular DNA

Follow-up and indications for liver biopsy in HBeAg-negative chronic hepatitis B virus infection with persistently normal ALT: A systematic review

Hepatitis B core-related antigen (HBcrAg) levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with genotypes A and D

Performance Evaluation of New Automated Hepatitis B Viral Markers in the Clinical Laboratory

EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection

Sexually Transmitted Infections Treatment Guidelines, 2021

Risk stratification for hepatitis B virus related hepatocellular carcinoma

Changes of HBsAg and HBV DNA levels in Chinese chronic hepatitis B patients after 5 years of entecavir treatment

Modeling host interactions with hepatitis B virus using primary and induced pluripotent stem cell-derived hepatocellular systems

Serum Levels of Hepatitis B Surface Antigen and DNA Can Predict Inactive Carriers With Low Risk of Disease Progression

Sequential Combination Therapy with Pegylated Interferon Leads to Loss of Hepatitis B Surface Antigen and Hepatitis B e Antigen (HBeAg) Seroconversion in HBeAg-Positive Chronic Hepatitis B Patients Receiving Long-Term Entecavir Treatment

EASL Recommendations on Treatment of Hepatitis C 2018

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

Ultrasound Elastography: Review of Techniques and Clinical Applications

Hepatitis B Surface Antigen Serum Levels Help to Distinguish Active From Inactive Hepatitis B Virus Genotype D Carriers

Repeated Measurements of Hepatitis B Surface Antigen Identify Carriers of Inactive HBV During Long-term Follow-up

Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: On-treatment kinetics of HBsAg serum levels vary by HBV genotype

Liver stiffness in the hepatitis B virus carrier: A non-invasive marker of liver disease influenced by the pattern of transaminases